Interestingly, the genomic profile of our case (MET, CCND1, FGF19, FGF3, and FGF4 amplification, NFKBIA, and TERT promoter mutation) resembles both the molecular landscape of LEL-HCC and LEL-CC. This evidence concerns the gene FGF19 and cholangiocarcinoma.